2024-10-01 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**1. Performance Comparison:**

* **Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company that develops and manufactures therapeutic antibodies for a variety of diseases.
* **Cumulative Return:** REGN: 102.39%, VOO (S&P 500): 133.28%
* **Performance Gap:** REGN is currently lagging behind the S&P 500 by 30.89%. This puts it at the 42.93rd percentile of its historical performance range (relative to the S&P 500).

**2. Recent Price Movement:**

* **Closing Price:** $1062.5
* **5-day Moving Average:** $1050.82
* **20-day Moving Average:** $1127.32
* **60-day Moving Average:** $1117.53

The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a downward trend.

**3. Technical Indicators:**

* **RSI:** 33.53 (below 50, indicating oversold conditions)
* **PPO:** -1.24 (negative, suggesting bearish momentum)
* **Delta_Previous_Relative_Divergence:** -21.44 (negative, indicating a short-term downward trend in relative strength)
* **Expected Return:** 0.0% (based on current investment and a 5-year projection)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

Regeneron has demonstrated strong earnings growth, exceeding analyst estimates in recent quarters. However, the stock has been underperforming, possibly due to concerns about the company's future growth prospects.

**5. News and Recent Issues:**

* **Recent Market Outlook:** The market outlook for REGN is currently uncertain, with analysts expressing mixed opinions on the company's future prospects.
* **Analyst Opinions:** Some analysts believe that Regeneron is undervalued and poised for growth, citing its strong pipeline of new drugs and its dominant position in the market for certain treatments. Others are concerned about the company's dependence on a few key products, and its vulnerability to competition.
* **Performance Highlights:** While Regeneron has delivered strong financial performance in recent quarters, the stock has been lagging behind the broader market. This is likely due to the concerns outlined above.

**6. Comprehensive Analysis:**

Regeneron Pharmaceuticals Inc. (REGN) is a strong company with a solid track record of earnings growth. However, the stock is currently lagging behind the market due to concerns about future growth prospects and dependence on key products. Technical indicators suggest that the stock is currently oversold, but its downward trend may continue in the short term. Investors should carefully consider the company's future prospects and potential risks before investing in REGN.

**7. Report in English:**

This analysis indicates that REGN is currently underperforming the market. The company has demonstrated strong earnings growth, but concerns regarding future growth and dependence on key products have dampened investor sentiment. The stock is currently oversold, but the short-term outlook is uncertain. While REGN remains a strong company, investors should carefully consider the potential risks and rewards before investing. 
